The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
Open accessAbstract
Inherited loss-of-function mutations in BRCA1 and BRCA2 and other tumor suppressor genes predispose to ovarian carcinomas, but the overall burden of disease due to inherited mutations is not known. Using targeted capture and massively parallel genomic sequencing, we screened for germ-line mutations in 21 tumor suppressor genes in genomic DNA from women with primary ovarian, peritoneal, or fallopian tube carcinoma. Subjects were consecutively enrolled at diagnosis and not selected for age or family history. All classes of mutations, including point mutations and large genomic deletions and insertions, were detected. Of 360 subjects, 24% carried germ-line loss-of-function mutations: 18% in BRCA1 or BRCA2 and 6% in BARD1 , BRIP1 , CHEK2 , MRE11A , MSH6 , NBN , PALB2 , RAD50 , RAD51C , or TP53 . Six of these genes were not previously implicated in inherited ovarian carcinoma. Primary carcinomas were generally characterized by genomic loss of normal alleles of the mutant genes. Of women with inherited mutations, >30% had no family history of breast or ovarian carcinoma, and >35% were 60 y or older at diagnosis. More patients with ovarian carcinoma carry cancer-predisposing mutations and in more genes than previously appreciated. Comprehensive genetic testing for inherited carcinoma is warranted for all women with ovarian, peritoneal, or fallopian tube carcinoma, regardless of age or family history. Clinical genetic testing is currently done gene by gene, with each test costing thousands of dollars. In contrast, massively parallel sequencing allows such testing for many genes simultaneously at low cost.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Self-citationCancer risk in mutation carriers of DNA-mismatch-repair genes
Aarnio, M., Sankila, R., Pukkala, E., Salovaara, R., Aaltonen, L. A., de la Chapelle, A., Peltom�ki, P., Mecklin, J.-P., & J�rvinen, H. J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990412)81:2<214::aid-ijc8>3.0.co;2-l · Cited by 1,278
Rebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn442 · Cited by 939
Meindl, A., Hellebrand, H., Wiek, C., Erven, V., Wappenschmidt, B., Niederacher, D., Freund, M., Lichtner, P., Hartmann, L., Schaal, H., et al. (2010) · Nature Genetics · doi:10.1038/ng.569 · Cited by 743
Extracolonic cancer in hereditary nonpolyposis colorectal cancer
Watson, P., & Lynch, H. T. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3<677::aid-cncr2820710305>3.0.co;2-# · Cited by 738
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
Pal, T., Permuth‐Wey, J., Betts, J. A., Krischer, J. P., Fiorica, J., Arango, H., LaPolla, J., Hoffman, M., Martino, M. A., Wakeley, K., et al. (2005) · Cancer · doi:10.1002/cncr.21536 · Cited by 691
Spectrum of Mutations in BRCA1, BRCA2, CHEK2, and TP53 in Families at High Risk of Breast Cancer
Walsh, T., Casadei, S., Coats, K. H., Swisher, E., Stray, S. M., Higgins, J., Roach, K. C., Mandell, J., Lee, M. K., Ciernikova, S., et al. (2006) · JAMA · doi:10.1001/jama.295.12.1379 · Cited by 666
Self-citationKauff, N. D., Domchek, S. M., Friebel, T. M., Robson, M. E., Lee, J., Garber, J. E., Isaacs, C., Evans, D. G., Lynch, H., Eeles, R. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9626 · Cited by 589
Germline mutations in RAD51D confer susceptibility to ovarian cancer
Breast Cancer Susceptibility Collaboration (UK), Loveday, C., Turnbull, C., Ramsay, E., Hughes, D., Ruark, E., Frankum, J. R., Bowden, G., Kalmyrzaev, B., Warren-Perry, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.893 · Cited by 534
Walsh, T., Lee, M. K., Casadei, S., Thornton, A. M., Stray, S. M., Pennil, C., Nord, A. S., Mandell, J. B., Swisher, E. M., & King, M.-C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007983107 · Cited by 487
Self-citationZhang, S., Royer, R., Li, S., McLaughlin, J. R., Rosen, B., Risch, H. A., Fan, I., Bradley, L., Shaw, P. A., & Narod, S. A. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.01.020 · Cited by 423
Susceptibility Pathways in Fanconi's Anemia and Breast Cancer
D'Andrea, A. D. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0809889 · Cited by 381
Domchek, S. M., Friebel, T. M., Neuhausen, S. L., Wagner, T., Evans, G., Isaacs, C., Garber, J. E., Daly, M. B., Eeles, R., Matloff, E., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70585-x · Cited by 327
Chetrit, A., Hirsh-Yechezkel, G., Ben-David, Y., Lubin, F., Friedman, E., & Sadetzki, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6905 · Cited by 323
Results From Four Rounds of Ovarian Cancer Screening in a Randomized Trial
Partridge, E., Kreimer, A. R., Greenlee, R. T., Williams, C., Xu, J.-L., Church, T. R., Kessel, B., Johnson, C. C., Weissfeld, J. L., Isaacs, C., et al. (2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31819cda77 · Cited by 258
Contribution of Inherited Mutations in the BRCA2-Interacting Protein PALB2 to Familial Breast Cancer
Casadei, S., Norquist, B. M., Walsh, T., Stray, S., Mandell, J. B., Lee, M. K., Stamatoyannopoulos, J. A., & King, M.-C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3958 · Cited by 240
Self-citationAccurate and exact CNV identification from targeted high-throughput sequence data
Nord, A. S., Lee, M., King, M.-C., & Walsh, T. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-184 · Cited by 208
Self-citationA polymorphic stop codon in BRCA2
Mazoyer, S., Dunning, A. M., Serova, O., Dearden, J., Puget, N., Healey, C. S., Gayther, S. A., Mangion, J., Stratton, M. R., Lynch, H. T., et al. (1996) · Nature Genetics · doi:10.1038/ng1196-253 · Cited by 174
Kuusisto, K. M., Bebel, A., Vihinen, M., Schleutker, J., & Sallinen, S. (2011) · Breast Cancer Research · doi:10.1186/bcr2832 · Cited by 131
Wong‐Brown, M. W., Nordfors, C., Mossman, D., Pecenpetelovska, G., Avery‐Kiejda, K. A., Talseth‐Palmer, B. A., Bowden, N. A., & Scott, R. J. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1443-0 · Cited by 105
Cancer predisposing BARD1 mutations in breast–ovarian cancer families
Ratajska, M., Antoszewska, E., Piskorz, A., Brożek, I., Borg, Å., Kusmierek, H., Biernat, W., & Limon, J. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1403-8 · Cited by 96
Sodha, N., Bullock, S. L., Taylor, R., Mitchell, G., Guertl‐Lackner, B., Williams, R. D., Bevan, S., Bishop, K., McGuire, S., Houlston, R. S., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600637 · Cited by 72
Abel, H., Duncavage, E. J., Becker, N., Armstrong, J. R., Magrini, V. J., & Pfeifer, J. D. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq528 · Cited by 58
Sauer, M. K., & Andrulis, I. L. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.030049 · Cited by 51
kConFab Investigators, Jekimovs, C., Chen, X., Arnold, J. M., Gatei, M. H., Richard, D. J., Spurdle, A. B., Khanna, K. K., & Chenevix‐Trench, G. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602381 · Cited by 44
BRCAs, I., Guénard, F., Labrie, Y., Ouellette, G., Joly Beauparlant, C., Simard, J., & Durocher, F. (2008) · Journal of Human Genetics · doi:10.1007/s10038-008-0285-z · Cited by 38
Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort
McInerney, N. M., Miller, N., Rowan, A., Colleran, G., Barclay, E., Curran, C., Kerin, M. J., Tomlinson, I. P. M., & Sawyer, E. J. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0540-9 · Cited by 35
Cancer predisposing BARD1 mutations in breast-ovarian cancer families
Ratajska, M., Matusiak, M., Brożek, I., Stukan, M., Śniadecki, M., Dębniak, J., Wydra, D. G., & Limon, J. (2012) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-10-s4-a10 · Cited by 10
Cited by
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
Pennington, K. P., Walsh, T., Harrell, M. I., Lee, M. K., Pennil, C. C., Rendi, M. H., Thornton, A., Norquist, B. M., Casadei, S., Nord, A. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2287 · Cited by 1,051
Self-citationHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
Ovarian cancer in the world: epidemiology and risk factors
Momenimovahed, Z., Tiznobaik, A., Taheri, S., & Salehiniya, H. (2019) · International Journal of Women's Health · doi:10.2147/ijwh.s197604 · Cited by 912
Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins
Prakash, R., Zhang, Y., Feng, W., & Jasin, M. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016600 · Cited by 869
Metadata
- Authors
- Walsh, T., Casadei, S., Lee, M. K., Pennil, C. C., Nord, A. S., Thornton, A. M., Roeb, W., Agnew, K. J., Stray, S. M., Wickramanayake, A., Norquist, B., Pennington, K. P., Garcia, R. L., King, M.-C., & Swisher, E. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2011-10-17
- Volume
- 108
- Issue
- 44
- Pages
- 18032-18037
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2169983032
- Cited by
- 933
- References
- 32
- FWCI
- 26.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.